Coexistent anaplastic and differentiated thyroid carcinoma - An immunohistochemical study

被引:32
作者
Aratake, Y
Nomura, H
Kotani, T
Marutsuka, K
Kobayashi, K
Kuma, K
Miyauchi, A
Okayama, A
Tamura, K
机构
[1] Fukuoka Univ, Dept Internal Med, Fukuoka 8140180, Japan
[2] Miyazaki Univ Hosp, Cent Lab Clin Invest, Miyazaki, Japan
[3] Miyazaki Univ Hosp, Dept Lab Med, Miyazaki, Japan
[4] Miyazaki Univ Hosp, Dept Pathol, Miyazaki, Japan
[5] Ohetsu Hosp, Tokushima, Japan
[6] Kuma Hosp, Kobe, Hyogo, Japan
关键词
immunohistochemistry; anaplastic thyroid carcinoma; Apaf-1; CD26/dipeptidyl peptidase IV; galectin-3; E-cadherin; CD147/extracellular matrix metalloproteinase inducer;
D O I
10.1309/LF3Q1NQKMT2N9KNV
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of the present study vas to clarify the underlying molecules that might contribute to the highly aggressive behavior of anaplastic thyroid carcinoma. We selected 5 cases of anaplastic thyroid carcinoma that had a differentiated areas to determine differences in the molecules of undifferentiated and differentiated cancer cells. We immunohistochemically examined the localization of nuclear antigen (Ki-67), proliferating cell nuclear antigen (PCNA), p53, apoptotic protease-activating factor-1 (Apaf-1), CD26, galectin-3, E-cadherin, and CD147. We found increased Ki-67, PCNA, and p53 labeling indices; decreased levels of Apaf-1, CD26, galectin-3, and E-cadherin; and overexpression of CD147 in the undifferentiated area compared with the differentiated area. These findings indicate high proliferative properties, suppression of opoptosis, disruption of cell-cell interaction, and induction of matrix metalloproteinases in the undifferentiated areas. Thus the molecules examined might be useful for evaluating the aggressive nature Of this tumor and the prognosis.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 53 条
  • [11] STEPWISE PARTICIPATION OF P53 GENE MUTATION DURING DEDIFFERENTIATION OF HUMAN THYROID CARCINOMAS
    DOBASHI, Y
    SUGIMURA, H
    SAKAMOTO, A
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (01) : 9 - 14
  • [12] Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas
    Ensinger, C
    Spizzo, G
    Moser, P
    Tschoerner, I
    Prommegger, R
    Gabriel, M
    Mikuz, G
    Schmid, KW
    [J]. SIGNAL TRANSDUCTION PATHWAYS, CHROMATIN STRUCTURE, AND GENE EXPRESSION MECHANISMS AS THERAPEUTIC TARGETS, 2004, 1030 : 69 - 77
  • [13] Ensinger C, 2003, ANTICANCER RES, V23, P2349
  • [14] Erickson LA, 1998, MODERN PATHOL, V11, P169
  • [16] HIGH PREVALENCE OF MUTATIONS OF THE P53 GENE IN POORLY DIFFERENTIATED HUMAN THYROID CARCINOMAS
    FAGIN, JA
    MATSUO, K
    KARMAKAR, A
    CHEN, DL
    TANG, SH
    KOEFFLER, HP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) : 179 - 184
  • [17] NUCLEAR-DNA IN ANAPLASTIC THYROID-CARCINOMA WITH A DIFFERENTIATED COMPONENT
    GALERADAVIDSON, H
    BIBBO, M
    DYTCH, HE
    GONZALEZCAMPORA, R
    FERNANDEZ, A
    WIED, GL
    [J]. HISTOPATHOLOGY, 1987, 11 (07) : 715 - 722
  • [18] Garcia-Rostan G, 1999, CANCER RES, V59, P1811
  • [19] Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas the thyroid
    Hunt, JL
    Tometsko, M
    LiVolsi, VA
    Swalsky, PO
    Finkelstein, SD
    Barnes, EL
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (12) : 1559 - 1564
  • [20] Inohara H, 1999, CANCER, V85, P2475, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO